Immunology News and Research

Latest Immunology News and Research

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.

17 Mar 2011

New omalizumab medication may reduce seasonal asthma attacks in children

A new anti-asthma medication dramatically reduced increases in seasonal asthma attacks in children and young adults with allergic asthma, according to a multi-institutional study involving a UT Southwestern Medical Center physician.

17 Mar 2011

Research highlights new parameters for HIV study

A research article co-authored by Brenna Anderson, MD, director of Reproductive Infectious Diseases Consultation in the Division of Maternal-Fetal Medicine at Women & Infants Hospital of Rhode Island, was included in the recently published special issue of the American Journal of Reproductive Immunology.

17 Mar 2011

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Neurologix, Inc., announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease were published in an online-first edition of The Lancet Neurology.

17 Mar 2011

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson's patients, according to results of a Phase 2 study published today in the journal Lancet Neurology. The approach introduces a gene into the brain to normalize chemical signaling.

16 Mar 2011

Aerocrine and Meditab partner for Allergy offices across the US.

Aerocrine AB today announced the launch of a strategic alliance with Meditab Software Inc. at the American Association of Allergy, Asthma and Immunology annual meeting in San Francisco on March 19-21.

16 Mar 2011

Apeiron in antitumor substances deal with Cleveland Clinic

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.

15 Mar 2011

Additional research needed for oral PrEP to treat HIV

The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis can be implemented on a large scale, according to an article in AIDS Patient Care and STDs, a peer-reviewed journal published by Mary Ann Liebert, Inc.

15 Mar 2011

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Oxford BioMedica plc, a leading gene therapy company, today announces that further analyses of the TroVax Renal Immunotherapy Survival Trial, a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology, Immunotherapy, the official journal of the Association for Cancer Immunotherapy.

15 Mar 2011

Study provides insight into why older adults are so vulnerable to pneumonia

A study featured on the cover of the March 15 Journal of Immunology is providing insight into why the elderly are so vulnerable to pneumonia and other bacterial infections.

15 Mar 2011

Scientists show how E. coli strain causes infection in individuals

Scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, have shown how the O157:H7 strain of Escherichia coli causes infection and thrives by manipulating the host immune response.

15 Mar 2011

New research may shed light on possible treatments for prion diseases

New research by Chongsuk Ryou, researcher at the UK Sanders-Brown Center on Aging and professor of microbiology, immunology and molecular genetics in the UK College of Medicine, may shed light on possible treatments for prion diseases.

15 Mar 2011

Study provides insight into aging immune system

A study featured on the cover of the March 15 Journal of Immunology is providing insight into why the elderly are so vulnerable to pneumonia and other bacterial infections.

14 Mar 2011

Peanut allergy has a genetic link: Study

A new study suggests that children with a certain gene defect are more likely to develop a peanut allergy. They studied the effect of changes in the gene filaggrin, which helps the skin block out allergens. They noted what has been seen before – the changes in the gene reduce the effectiveness of the barrier, increasing the risk for eczema and asthma.

14 Mar 2011

Breast fed babies smarter: Study

Scientists have finally come to a consensus that babies who are breast fed grow up to be more intelligent. A latest study showed that just four weeks on their mothers’ milk can have a ‘significant’ effect on a child’s development in primary and secondary school. These children do better at reading, writing and maths at the ages of five, seven, 11 and 14. It was known till now that breast feeding boosts immunity and helps the children fight ear infections, stomach bugs and even asthma.

14 Mar 2011

New drug for Lupus approved

A new drug for lupus has won U.S. approval. The drug, Benlysta from Human Genome Sciences Inc., is administered once a month intravenously.

12 Mar 2011

Flu pandemics may return & mutating strains: Studies

Scientists have warned that we have not seen the end of H1N1 swine flu that swept the globe in 2009/10. The strain of the virus could easily morph into a more transmissible form, while an older, mid-20th century virus could also come roaring back they say. Asian influenza, a H2N2 strain, first appeared in 1957 and killed one to four million people despite a major vaccination campaign. Studies have shown that most people today aged 50 or older retain some immunity to the virus, which continues to circulate in birds and swine. But the younger are more vulnerable they warn.

12 Mar 2011

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.

11 Mar 2011

Groundbreaking studies presented at Prostate Cancer Research Program's IMPaCT conference

Today, the nation's most prestigious minds in prostate cancer research unveiled the findings of their groundbreaking studies at the Prostate Cancer Research Program's (PCRP's) Innovative Minds in Prostate Cancer Today (IMPaCT) conference in Orlando, Florida.

11 Mar 2011

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

The Cancer Immunotherapy Consortium, a program of the nonprofit Cancer Research Institute, will host its 2011 Scientific Colloquium March 17-19, 2011, at the Gaylord National Hotel and Convention Center in National Harbor, MD.

11 Mar 2011